Skip to main content

Table 2 Types and severity of adverse events

From: 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis

  All AEs SAEs AEs Leading to discontinuation
Any 338 (168) 121 (89) 74
Infection 93 (81) 47 (42) 20
   Tuberculosisa 4 (4) 4 (4) 3
   Other bacterial Infection 38 (33) 29 (24) 10
   Viral Infection 8 (8) 5 (5) 1
   Opportunistic infectiona 8 (8) 3 (3) 2
   Other 35 (32) 6 (6) 4
Infusion reactionb 77 (64) 15 (15) 33
Dermatological disorders 40 (33) 2 (2) 4
Cardiovascular disorders 22 (20) 15 (13) 4
RA-related disease manifestations 17 (16) 11 (11) 2
Gastrointestinal disorders 17 (16) 1 (1) -
Respiratory disorders 11 (10) 4 (4) -
Neurologic disorder 11 (10) 1 (1) 1
Non-RA joint manifestations 8 (8) 4 (4) -
Tumora 7 (7) 6 (6) 5
   Benign 3 (3) 2 (2) 2
   Malignant 4 (4) 4 (4) 3
Traumatic event 7 (7) 4 (4) 1
Hematologic disorders 4 (4) 4 (4) 1
Psychiatric disorders 3 (3) 1 (1) 2
Liver toxicities 2 (2) 1 (1) -
Other 19 (16) 5 (5) 1
  1. Values are numbers of AEs, with the number of patients affected shown in parentheses.
  2. a See Supporting information in Additional file 1 for further details.
  3. b Individual infusion reactions are described in Table 3.
  4. AE, adverse event; RA, rheumatoid arthritis; SAE, serious adverse event.